1092580-04-5 Usage
General Description
5-Bromo-4-iodo-1H-pyrrolo[2,3-b]pyridine is a chemical compound with the molecular formula C7H4BrIN2. It is a heterocyclic compound containing a pyrrole ring fused to a pyridine ring, with bromine and iodine atoms attached to the pyrrole ring. 5-Bromo-4-iodo-1H-pyrrolo[2,3-b]pyridine has been of interest in medicinal chemistry due to its potential as a building block for the synthesis of bioactive molecules. It has been studied for its potential use in the development of pharmaceuticals, including in the treatment of cancer and other diseases. The compound's unique structure and reactivity make it a valuable tool for organic synthesis, and its potential pharmacological applications make it a focus of ongoing research in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1092580-04-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,2,5,8 and 0 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1092580-04:
(9*1)+(8*0)+(7*9)+(6*2)+(5*5)+(4*8)+(3*0)+(2*0)+(1*4)=145
145 % 10 = 5
So 1092580-04-5 is a valid CAS Registry Number.
1092580-04-5Relevant articles and documents
CHEMICAL COMPOUNDS
-
, (2021/04/02)
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.
PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS
-
, (2018/12/13)
The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.
